-
Je něco špatně v tomto záznamu ?
Dose to neuroanatomical structures surrounding pituitary adenomas and the effect of stereotactic radiosurgery on neuroendocrine function: an international multicenter study
IJ. Pomeraniec, Z. Xu, CC. Lee, HC. Yang, T. Chytka, R. Liscak, R. Martinez-Alvarez, N. Martinez-Moreno, L. Attuati, P. Picozzi, D. Kondziolka, M. Mureb, K. Bernstein, D. Mathieu, M. Maillet, A. Ogino, H. Long, H. Kano, LD. Lunsford, BE....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
PubMed
34560630
DOI
10.3171/2021.3.jns203812
Knihovny.cz E-zdroje
- MeSH
- adenom * patologie radioterapie MeSH
- hypopituitarismus * etiologie MeSH
- lidé MeSH
- nádory hypofýzy * diagnostické zobrazování etiologie radioterapie MeSH
- následné studie MeSH
- radiochirurgie * škodlivé účinky MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: Stereotactic radiosurgery (SRS) provides a safe and effective therapeutic modality for patients with pituitary adenomas. The mechanism of delayed endocrine deficits based on targeted radiation to the hypothalamic-pituitary axis remains unclear. Radiation to normal neuroendocrine structures likely plays a role in delayed hypopituitarism after SRS. In this multicenter study by the International Radiosurgery Research Foundation (IRRF), the authors aimed to evaluate radiation tolerance of structures surrounding pituitary adenomas and identify predictors of delayed hypopituitarism after SRS for these tumors. METHODS: This is a retrospective review of patients with pituitary adenomas who underwent single-fraction SRS from 1997 to 2019 at 16 institutions within the IRRF. Dosimetric point measurements of 14 predefined neuroanatomical structures along the hypothalamus, pituitary stalk, and normal pituitary gland were made. Statistical analyses were performed to determine the impact of doses to critical structures on clinical, radiographic, and endocrine outcomes. RESULTS: The study cohort comprised 521 pituitary adenomas treated with SRS. Tumor control was achieved in 93.9% of patients over a median follow-up period of 60.1 months, and 22.5% of patients developed new loss of pituitary function with a median treatment volume of 3.2 cm3. Median maximal radiosurgical doses to the hypothalamus, pituitary stalk, and normal pituitary gland were 1.4, 7.2, and 11.3 Gy, respectively. Nonfunctioning adenoma status, younger age, higher margin dose, and higher doses to the pituitary stalk and normal pituitary gland were independent predictors of new or worsening hypopituitarism. Neither the dose to the hypothalamus nor the ratio between doses to the pituitary stalk and gland were significant predictors. The threshold of the median dose to the pituitary stalk for new endocrinopathy was 10.7 Gy in a single fraction (OR 1.77, 95% CI 1.17-2.68, p = 0.006). CONCLUSIONS: SRS for the treatment of pituitary adenomas affords a high tumor control rate with an acceptable risk of new or worsening endocrinopathy. This evaluation of point dosimetry to adjacent neuroanatomical structures revealed that doses to the pituitary stalk, with a threshold of 10.7 Gy, and doses to the normal gland significantly increased the risk of post-SRS hypopituitarism. In patients with preserved pre-SRS neuroendocrine function, limiting the dose to the pituitary stalk and gland while still delivering an optimal dose to the tumor appears prudent.
Centro Gamma Knife Dominicano and Radiology Department CEDIMAT Santo Domingo Dominican Republic
Department of Neurosurgery Humanitas Clinical and Research Center IRCCS Rozzano Milan Italy
Department of Neurosurgery University of Louisville Hospital Louisville Kentucky
Department of Neurosurgery University of Pittsburgh Medical Center Pittsburgh Pennsylvania
Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech Republic
Departments of10Neurosurgery and
Departments of13Neurosurgery and
Departments of15Neurosurgery and
Departments of18Neurological Surgery and
Departments of8Neurosurgery and
Division of Radiation Oncology University of Alberta Edmonton Alberta Canada
Gamma Knife Center Jewish Hospital Mayfield Clinic Cincinnati Ohio
Medicine and Endocrinology University of Virginia Health Science Center Charlottesville Virginia
Radiation Oncology NYU Langone Medical Center New York New York
Radiation Oncology Penn State Health Hershey Medical Center Hershey Pennsylvania
Radiation Oncology University of Southern California Keck School of Medicine Los Angeles California
Radiation Oncology West Virginia University Medical Center Morgantown West Virginia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019667
- 003
- CZ-PrNML
- 005
- 20220804135901.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3171/2021.3.JNS203812 $2 doi
- 035 __
- $a (PubMed)34560630
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pomeraniec, I Jonathan $u Departments of1Neurosurgery
- 245 10
- $a Dose to neuroanatomical structures surrounding pituitary adenomas and the effect of stereotactic radiosurgery on neuroendocrine function: an international multicenter study / $c IJ. Pomeraniec, Z. Xu, CC. Lee, HC. Yang, T. Chytka, R. Liscak, R. Martinez-Alvarez, N. Martinez-Moreno, L. Attuati, P. Picozzi, D. Kondziolka, M. Mureb, K. Bernstein, D. Mathieu, M. Maillet, A. Ogino, H. Long, H. Kano, LD. Lunsford, BE. Zacharia, C. Mau, LC. Tuanquin, C. Cifarelli, D. Arsanious, J. Hack, RE. Warnick, BA. Strickland, G. Zada, EL. Chang, H. Speckter, S. Patel, D. Ding, D. Sheehan, K. Sheehan, S. Kvint, LY. Buch, AR. Haber, J. Shteinhart, ML. Vance, JP. Sheehan
- 520 9_
- $a OBJECTIVE: Stereotactic radiosurgery (SRS) provides a safe and effective therapeutic modality for patients with pituitary adenomas. The mechanism of delayed endocrine deficits based on targeted radiation to the hypothalamic-pituitary axis remains unclear. Radiation to normal neuroendocrine structures likely plays a role in delayed hypopituitarism after SRS. In this multicenter study by the International Radiosurgery Research Foundation (IRRF), the authors aimed to evaluate radiation tolerance of structures surrounding pituitary adenomas and identify predictors of delayed hypopituitarism after SRS for these tumors. METHODS: This is a retrospective review of patients with pituitary adenomas who underwent single-fraction SRS from 1997 to 2019 at 16 institutions within the IRRF. Dosimetric point measurements of 14 predefined neuroanatomical structures along the hypothalamus, pituitary stalk, and normal pituitary gland were made. Statistical analyses were performed to determine the impact of doses to critical structures on clinical, radiographic, and endocrine outcomes. RESULTS: The study cohort comprised 521 pituitary adenomas treated with SRS. Tumor control was achieved in 93.9% of patients over a median follow-up period of 60.1 months, and 22.5% of patients developed new loss of pituitary function with a median treatment volume of 3.2 cm3. Median maximal radiosurgical doses to the hypothalamus, pituitary stalk, and normal pituitary gland were 1.4, 7.2, and 11.3 Gy, respectively. Nonfunctioning adenoma status, younger age, higher margin dose, and higher doses to the pituitary stalk and normal pituitary gland were independent predictors of new or worsening hypopituitarism. Neither the dose to the hypothalamus nor the ratio between doses to the pituitary stalk and gland were significant predictors. The threshold of the median dose to the pituitary stalk for new endocrinopathy was 10.7 Gy in a single fraction (OR 1.77, 95% CI 1.17-2.68, p = 0.006). CONCLUSIONS: SRS for the treatment of pituitary adenomas affords a high tumor control rate with an acceptable risk of new or worsening endocrinopathy. This evaluation of point dosimetry to adjacent neuroanatomical structures revealed that doses to the pituitary stalk, with a threshold of 10.7 Gy, and doses to the normal gland significantly increased the risk of post-SRS hypopituitarism. In patients with preserved pre-SRS neuroendocrine function, limiting the dose to the pituitary stalk and gland while still delivering an optimal dose to the tumor appears prudent.
- 650 12
- $a adenom $x patologie $x radioterapie $7 D000236
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hypopituitarismus $x etiologie $7 D007018
- 650 12
- $a nádory hypofýzy $x diagnostické zobrazování $x etiologie $x radioterapie $7 D010911
- 650 12
- $a radiochirurgie $x škodlivé účinky $7 D016634
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Xu, Zhiyuan $u Departments of1Neurosurgery
- 700 1_
- $a Lee, Cheng-Chia $u 4Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei City, Taiwan
- 700 1_
- $a Yang, Huai-Che $u 4Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei City, Taiwan
- 700 1_
- $a Chytka, Tomas $u 5Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Liscak, Roman $u 5Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Martinez-Alvarez, Roberto $u 6Radiosurgery Unit, Hospital Ruber Internacional, Madrid, Spain
- 700 1_
- $a Martinez-Moreno, Nuria $u 6Radiosurgery Unit, Hospital Ruber Internacional, Madrid, Spain
- 700 1_
- $a Attuati, Luca $u 7Department of Neurosurgery, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy
- 700 1_
- $a Picozzi, Piero $u 7Department of Neurosurgery, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy
- 700 1_
- $a Kondziolka, Douglas $u Departments of8Neurosurgery and
- 700 1_
- $a Mureb, Monica $u Departments of8Neurosurgery and
- 700 1_
- $a Bernstein, Kenneth $u 9Radiation Oncology, NYU Langone Medical Center, New York, New York
- 700 1_
- $a Mathieu, David $u Departments of10Neurosurgery and
- 700 1_
- $a Maillet, Michel $u 11Endocrinology, Université de Sherbrooke, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Quebec, Canada
- 700 1_
- $a Ogino, Akiyoshi $u 12Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 700 1_
- $a Long, Hao $u 12Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 700 1_
- $a Kano, Hideyuki $u 12Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 700 1_
- $a Lunsford, L Dade $u 12Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 700 1_
- $a Zacharia, Brad E $u Departments of13Neurosurgery and
- 700 1_
- $a Mau, Christine $u Departments of13Neurosurgery and
- 700 1_
- $a Tuanquin, Leonard C $u 14Radiation Oncology, Penn State Health-Hershey Medical Center, Hershey, Pennsylvania
- 700 1_
- $a Cifarelli, Christopher $u Departments of15Neurosurgery and
- 700 1_
- $a Arsanious, David $u Departments of15Neurosurgery and
- 700 1_
- $a Hack, Joshua $u 16Radiation Oncology, West Virginia University Medical Center, Morgantown, West Virginia
- 700 1_
- $a Warnick, Ronald E $u 17Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio
- 700 1_
- $a Strickland, Ben A $u Departments of18Neurological Surgery and
- 700 1_
- $a Zada, Gabriel $u Departments of18Neurological Surgery and
- 700 1_
- $a Chang, Eric L $u 19Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, California
- 700 1_
- $a Speckter, Herwin $u 20Centro Gamma Knife Dominicano and Radiology Department, CEDIMAT, Santo Domingo, Dominican Republic
- 700 1_
- $a Patel, Samir $u 21Division of Radiation Oncology, University of Alberta, Edmonton, Alberta, Canada
- 700 1_
- $a Ding, Dale $u 22Department of Neurosurgery, University of Louisville Hospital, Louisville, Kentucky; and
- 700 1_
- $a Sheehan, Darrah $u Departments of1Neurosurgery
- 700 1_
- $a Sheehan, Kimball $u Departments of1Neurosurgery
- 700 1_
- $a Kvint, Svetlana $u 23Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- 700 1_
- $a Buch, Love Y $u 23Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- 700 1_
- $a Haber, Alexander R $u 23Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- 700 1_
- $a Shteinhart, Jacob $u 23Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- 700 1_
- $a Vance, Mary Lee $u Departments of1Neurosurgery $u 2Radiation Oncology, and $u 3Medicine and Endocrinology, University of Virginia Health Science Center, Charlottesville, Virginia
- 700 1_
- $a Sheehan, Jason P $u Departments of1Neurosurgery $u 2Radiation Oncology, and
- 773 0_
- $w MED00002843 $t Journal of neurosurgery $x 1933-0693 $g Roč. 136, č. 3 (2022), s. 813-821
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34560630 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135855 $b ABA008
- 999 __
- $a ok $b bmc $g 1823040 $s 1170910
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 136 $c 3 $d 813-821 $e 20210924 $i 1933-0693 $m Journal of neurosurgery $n J Neurosurg $x MED00002843
- LZP __
- $a Pubmed-20220720
